We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Avadel AVDL
An SI Board Since April 2003
Posts SubjectMarks Bans
240 26 0
Emcee:  Arthur Radley Type:  Unmoderated
If one can get beyond the fact that (FLML) is a French domiciled company, it has IMO very intriguing issues to consider for a biotech firm. For starters, they are actually one of the few biotechs that are showing earnings and a profit.

For me, the reason I've held this stock for several years is my opinion that most of the major drug companies are facing the onslaught of generic drugs eroding their "money-makers" ,and to regain control over these drugs they will need to reformulate them. A new delivery is one way to accomplish this.

What FLML has to offer is a unique and proprietary drug delivery platform. They have several partnerships in this area, but the one that has my attention is the deal(S) they have with Glaxo. Last July(02), they signed a deal with Glaxo for their Augmentin drug. On 3/29/03, Glaxo signed another deal with FLML...indicating at least to me, they like what they have seen with the '02 Augmentin deal.

FLML has several other undisclosed product develop deals with major companies.

Also, on 3/25.03, FLML announce positive results for their Basulin diabetic product. They are seeking a partnership for this product...and any announcement with a major company will be a major positive.

FLML has been very strong in 2003..Currently it is up about 70% YTD, and if you look at the current TA for the stock you will find...

If one follows TA on stocks, then the current chart on FLML indicates that better things are ahead....

"FLML shows a substantial positive divergence from its 200-day moving average line of more than 75%. Generally, the greater the difference between a stock's price and this important long-term technical indicator, the steeper will be that stock's long-term uptrend. A divergence this large from the 200-day line ranks in the top five percent of the market and is a bullish indication of long-term strength for FLML."

I have owned this stock for three years...and recently added more. Would welcome any discussion.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
240Avadel Pharmaceuticals' (AVDL) CEO Michael Anderson on Q4 2017 Results - EarPaul Lee-3/8/2018
239Does Avadel Pharmaceuticals Have The Potential To 10-Double? seekingalpha.comPaul Lee-3/8/2018
238Avadel Pharmaceuticals Announces Data Presentation for Noctivaâ„¢ at The American Paul Lee-10/5/2017
237Flamel Technologies Doses First Patient in REST-ON Phase III Trial of FT218 for Paul Lee-12/16/2016
236Flamel Technologies Reaches Agreement With FDA on Protocol for Phase III PivotalPaul Lee-10/6/2016
235 Jazz Makes Deal In Xyrem IP Fight With Ranbaxy, Sun, Ohm By Kevin Penton Law3Paul Lee-6/2/2016
234 Jazz Makes Deal In Xyrem IP Fight With Ranbaxy, Sun, Ohm By Kevin Penton LaPaul Lee-6/2/2016
233Flamel Technologies Provides Update on Corporate Progress Clinical PPaul Lee-1/8/2016
232 The Neostigmine Shortage: A Clinical Conundrum with Few Drug Alternatives by StPaul Lee-10/22/2015
231 Flamel Ireland Limited Licenses LiquiTime(R) Technology to Perrigo for U.S. OPaul Lee-10/5/2015
230We'd like to have a logo on this board as part of our site modernizatioSI Ron (Crazy Soup Man)-12/19/2014
229 Flamel Technologies Announces Positive Results of a Second Clinical Trial WitPaul Lee-12/19/2014
228Has been a long haul on this one! Took transforming the company to get here, butArthur Radley-12/3/2014
227quicktake.morningstar.comArthur Radley-3/20/2010
226In this horrible market today, FLML swam against the tide...not great volume, buArthur Radley-1/20/2010
225My guess is that they figured this would be the quickest venue to get another drArthur Radley-12/18/2009
224Maybe i'll be proven wrong but off hand i don't think the world needs anrkrw-12/18/2009
223New trial for the Medusa program.......and stock is basically dead in the water.Arthur Radley-12/18/2009
222online.barrons.comArthur Radley-11/28/2009 Why I still think FLML has a future.......maybe one day!Arthur Radley-11/24/2009
220Q report is now on schedule for Friday of this week. The key will be whether theArthur Radley-11/4/2009
219Flamel Technologies Announces Licensing Agreement with Pfizer 8:00 am ET 11/04/2Arthur Radley-11/4/2009 Would suggest all listen to the UBS presentation this morning.Arthur Radley-9/22/2009
217Took a position in the stock this morning...@$9.47Arthur Radley-9/18/2009
216Stock pulled back today in overall down market........but with new 52 week high Arthur Radley-9/1/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):